What important information should be communicated to patients undergoing isoniazid (INH) therapy?

Isoniazid (INH) is primarily used in the treatment of tuberculosis and is known to have certain adverse effects, one of which is peripheral neuropathy. This condition arises due to the drug's interference with vitamin B6 (pyridoxine) metabolism in the body. When patients are informed that peripheral neuropathy is a possible adverse effect of INH, they are also made aware that this condition can be mitigated by co-administering pyridoxine. This is crucial information because it allows patients to take proactive measures to prevent or alleviate the symptoms associated with neuropathy, enhancing their overall treatment experience.

Understanding this potential side effect and the role of pyridoxine not only equips patients with knowledge about what to expect during their therapy but also reassures them that there is a reversible component to the adverse effect. This enables better adherence to the treatment plan and reduces anxiety related to medication side effects.